Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Neuroendocrine Theranostics.

Created on 17 Nov 2026

Authors

Michael Kavanaugh

Published in

Magnetic resonance imaging clinics of North America. Volume 35. Issue 1. Pages 189-197. Epub Oct 23, 2026.

Abstract

Neuroendocrine neoplasms are a rare and heterogeneous group of neoplasms originating from a wide range of primary organs, with differing treatment approaches and prognoses. Most well-differentiated neuroendocrine tumors (NETs), particularly gastroenteropancreatic NETs, highly express somatostatin receptors (SSTRs) on their cell membranes, and thus SSTR-targeting therapies play a crucial role in management. SSTR-targeting peptide receptor radionuclide therapy uses radiolabeled somatostatin analogs that decay via particle emission, resulting in targeted delivery of therapeutic radiation to tumor sites while minimizing nontarget toxicity.

PMID:
43039499
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement